CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours

Launched by CEBIOTEX · May 15, 2025

Keywords

ClinConnect Summary

The CEB-01 clinical trial is studying a new treatment called CEB-01, which is designed to help children with certain types of abdominal tumors that can be surgically removed. This trial is for children and teenagers aged birth to 17 years who have been diagnosed with specific tumors, including soft-tissue sarcomas and neuroblastoma. The treatment involves a special biodegradable membrane that releases a chemotherapy drug directly into the area where the tumor was removed. This aims to prevent any remaining cancer cells from causing the tumor to return.

To be eligible for this trial, participants must be under 18 and have certain types of tumors that are categorized as either new or recurrent. They should also be in good overall health, having recovered from any previous treatments, and must have a life expectancy of more than six months. Throughout the trial, participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. This trial is currently recruiting participants, and it is an important opportunity for young patients to receive a potentially beneficial treatment alongside standard care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• To be eligible to participate in this trial, an individual must meet all the following criteria:
• • 1. ≤ 18 years.
• 2. Participants must have a diagnosis of:
• • 1. De novo or recurrent abdominal soft-tissue sarcoma.
• • 2. De novo or recurrent high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification, regardless of response to frontline therapy, diagnosed either by a former histologic verification of neuroblastoma and/or former demonstration of tumour cells in the bone marrow with increased urinary catecholamines at the time of study enrolment. Participants who were initially considered low or intermediate risk but were then reclassified as high risk are also eligible.
• • 3. Other tumours: recurrent Wilms tumour, de novo or recurrent Germ cell tumour, de novo or recurrent extracranial malignant rhabdoid tumour, de novo or recurrent synovial sarcoma, de novo or recurrent fibrolamellar hepatocellular carcinoma, and de novo or recurrent desmoplastic small round cell tumour.
• • 3. A histology assessment is required for enrolment of de novo cases. A new histology assessment is not required for enrolment of the recurrent cases, but it will be obtained from the resected tumour to assess whether the histology is identical to the original tumour.
• • 4. Participants previously treated with irinotecan will be eligible if they have not had documented progressive disease during treatment.
• • 5. Participants might have more than one surgically removable lesion.
• • 6. Adequate liver, renal, haematological, and cardiac function.
• • 7. Participants must have fully recovered from the acute toxic effects (Grade 3 or above) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this trial.
• • 8. Landky or Karnosfsky functional performance status score ≥ 50 at screening.
• • 9. Female participants of childbearing potential must have a negative urine betahuman chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
• • 10. Female and male participants of childbearing potential must be willing to use adequate contraception throughout the study and for 6 months after surgery.
• • 11. Life expectancy greater than 6 months.
• • 12. The participant legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained prior to any protocol screening procedures.
• • Exclusion Criteria
• An individual who meets any of the following criteria will be excluded from participation in this trial:
• • 1. Metastatic lesions.
• • 2. Other malignancies within past 2 years except for in-situ cancers or basal/squamous cell skin cancer. Subjects with other malignancies are eligible if they are disease-free for at least 24 months or have a clinically stable concurrent malignancy not requiring tumour-directed treatment.
• • 3. Active bacterial, viral or fungal infection.
• • 4. Known history of active human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C or chronic liver disease. Testing is not required in the absence of clinical findings or suspicion.
• • 5. Impossibility of ensuring adequate follow-up.
• • 6. Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
• • 7. Contraindication to computed tomography (CT) scan.
• • 8. Major surgery within 14 days prior to the implant of study drug or still in recovery after experiencing surgical complications; neither tumour biopsy nor central line insertion are considered a major surgery.
• • 9. Other relevant concomitant illnesses.
• • 10. Participant' status post-allogeneic stem cell transplant are not eligible.
• • 11. Participants with disease of any major organ system that would compromise their ability to withstand therapy.
• • 12. Patients with tumour size requiring CEB-01 implant that exceeds the maximum implantable surface area based on Body Surface Area (BSA) correction.
• • 13. Patients with known hypersensitivity to SN-38 or any of the CEB-01 excipients.
• • 14. Pregnancy or lactation. Pregnant women are excluded from this study; if the patient is a lactating mother, breastfeeding should be discontinued.